(AOF) – Following the announcement on June 5 of the proposed acquisition of Biocorp by Novo Nordisk, a leading global healthcare company headquartered in Denmark that develops treatments for diabetes and other chronic diseases), the representative bodies of BIOCORP personnel were informed and consulted and unanimously issued a favorable opinion on June 9 concerning this operation.
In this context, Biocorp announces the signing of an acquisition agreement between BIO JAG, main shareholder of Biocopr, and Novo Nordisk, relating to 1,998,800 Biocorp shares, representing 45.3% of the capital and 62.2% of the rights voting rights of Biocorp, for a price of 35 euros per share.
It is recalled that Novo Norddisk would acquire, concomitantly and subject to the acquisition of Bio Jag’s stake, at the same price per share, the shares held in Biocorp by certain minority shareholders, including Nyenburgh, Greenstock and Vatel Capital, representing together 19 % of the share capital and 13.1% of the theoretical voting rights of Biocorp.
The completion of the acquisition of the Control block and the filing of the offer are expected to take place during the third quarter of 2023.